SEATTLE and RICHMOND, BRITISH COLUMBIA — Monod Bio, an AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. The deal allows SignalChem Biotech to incorporate these technologies into custom luminescent assay development and protein-fusion services for third-party researchers.
The partnership is a strategic move for Sino Biological, which aims to integrate AI-enabled technologies across its global life science tools and services portfolio. By leveraging Monod Bio’s AI-designed proteins, SignalChem can offer researchers more efficient pathways to high-quality discovery candidates. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized the importance of this collaboration: “By incorporating Monod Bio’s AI-designed protein technologies into SignalChem’s custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently.”
Monod Bio’s LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance target recognition. Together, these technologies provide versatile tools for developing customized assays and discovery workflows. Daniel Silva Manzano, PhD, CEO of Monod Bio, highlighted the significance of the deal: “SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services.”
The licensing agreement is non-exclusive, allowing Monod Bio to partner with other companies, but it marks a significant step in commercializing AI-designed proteins for research use. For the life science industry, this development underscores the growing trend of incorporating computational design into drug discovery and assay development. The ability to create custom, high-performance proteins on demand could accelerate research timelines and improve the precision of biological assays.
SignalChem Biotech, known for its specialized reagents and contract research organization (CRO) services, will integrate these technologies into its existing offerings. Sino Biological, with facilities across Asia, North America, and Europe, aims to leverage this to enhance its global service capabilities. The company, however, noted in a disclaimer that the revenue from this business is not expected to have a material impact on its overall financial performance, given its broad product portfolio.
Monod Bio, based in Seattle, uses AI-powered de novo protein design to create novel binders, biosensors, and other functional proteins. Through its Monod Inside model, the company partners with life science firms to integrate its technologies into next-generation products and services. This licensing agreement is a prime example of that model in action.
For researchers and the broader scientific community, this partnership means greater access to advanced tools for custom assay development. The AI-designed proteins offer improved stability and performance, which could lead to more reliable and sensitive assays, ultimately aiding in the discovery of new therapeutics and diagnostics.
